Showing 13 to 20 of 20 results
NHS Approves Capivasertib for Advanced Breast Cancer
The NHS approved capivasertib, a twice-daily pill, for HR-positive HER2-negative breast cancer with specific gene mutations, benefiting up to 3,000 women yearly by extending progression-free survival by 4.2 months; this follows extensive research and clinical trials.
NHS Approves Capivasertib for Advanced Breast Cancer
The NHS approved capivasertib, a twice-daily pill, for HR-positive HER2-negative breast cancer with specific gene mutations, benefiting up to 3,000 women yearly by extending progression-free survival by 4.2 months; this follows extensive research and clinical trials.
Progress
36% Bias Score
Optune's Delayed Funding Highlights Flaws in Canada's Drug Approval Process
Despite Health Canada's 2022 approval and a 2017 study showing Optune's effectiveness in extending the lives of glioblastoma patients, its \$27,000 monthly cost and lack of provincial funding create significant delays and inequities in access across Canada.
Optune's Delayed Funding Highlights Flaws in Canada's Drug Approval Process
Despite Health Canada's 2022 approval and a 2017 study showing Optune's effectiveness in extending the lives of glioblastoma patients, its \$27,000 monthly cost and lack of provincial funding create significant delays and inequities in access across Canada.
Progress
56% Bias Score
UK Drug Approval Delays Cause Anxiety for Patients
Mike Thomas, diagnosed with MND in 2022, is experiencing slowed deterioration thanks to tofersen via an early access program; however, the drug's uncertain NHS future and differing access across the UK (exemplified by Sara and David's situations with omaveloxolone) highlight challenges in the nation...
UK Drug Approval Delays Cause Anxiety for Patients
Mike Thomas, diagnosed with MND in 2022, is experiencing slowed deterioration thanks to tofersen via an early access program; however, the drug's uncertain NHS future and differing access across the UK (exemplified by Sara and David's situations with omaveloxolone) highlight challenges in the nation...
Progress
48% Bias Score
EMA Approves Leqembi for Alzheimer's
The European Medicines Agency approves Leqembi, a new Alzheimer's treatment to reduce cognitive decline in early-stage patients. The drug targets amyloid plaques in the brain and has already received approvals in other countries.
EMA Approves Leqembi for Alzheimer's
The European Medicines Agency approves Leqembi, a new Alzheimer's treatment to reduce cognitive decline in early-stage patients. The drug targets amyloid plaques in the brain and has already received approvals in other countries.
Progress
0% Bias Score
EU's Slow Drug Approvals Delay Patient Access to Life-Saving Medicines
By 2050, one-third of the EU population will be over 65, underscoring the urgent need for health system modernization. Slower drug approvals (120 days behind the US and Japan) cause a 20-month delay in patient access to new medicines compared to the US, impacting those with cancer, cardiovascular di...
EU's Slow Drug Approvals Delay Patient Access to Life-Saving Medicines
By 2050, one-third of the EU population will be over 65, underscoring the urgent need for health system modernization. Slower drug approvals (120 days behind the US and Japan) cause a 20-month delay in patient access to new medicines compared to the US, impacting those with cancer, cardiovascular di...
Progress
52% Bias Score
NHS to Re-evaluate Alzheimer's Drugs Amidst Cost and Efficacy Concerns
The NHS is reviewing its decision to block two Alzheimer's drugs, lecanemab and donanemab, which slow disease progression by up to 35 percent but cost approximately £1 billion annually, after public and advocacy group pressure.
NHS to Re-evaluate Alzheimer's Drugs Amidst Cost and Efficacy Concerns
The NHS is reviewing its decision to block two Alzheimer's drugs, lecanemab and donanemab, which slow disease progression by up to 35 percent but cost approximately £1 billion annually, after public and advocacy group pressure.
Progress
56% Bias Score
EMA Approves Alzheimer's Drug Leqembi
The European Medicines Agency approves Leqembi, a new Alzheimer's drug, with strict conditions to mitigate serious side effects.
EMA Approves Alzheimer's Drug Leqembi
The European Medicines Agency approves Leqembi, a new Alzheimer's drug, with strict conditions to mitigate serious side effects.
Progress
0% Bias Score
French Health Authority Rejects Early Access to Biogen's ALS Drug
The French health authority denied early access to Biogen's ALS drug Qalsody due to insufficient clinical trial data, sparking controversy and raising questions about its potential effectiveness.
French Health Authority Rejects Early Access to Biogen's ALS Drug
The French health authority denied early access to Biogen's ALS drug Qalsody due to insufficient clinical trial data, sparking controversy and raising questions about its potential effectiveness.
Progress
0% Bias Score
Showing 13 to 20 of 20 results